PHASE III TRIAL OF EFAVIRENZ OR NELFINAVIR LAMIVUDINE &ZIDOVUDINE

$47,556M01FY2000RRNIH

Mount Sinai School Of Medicine Of Cuny, New York NY

Investigators

Linked publications & trials

Paper 39016335 Paper 38574825 Paper 38423369 Paper 37944567 Paper 36640190 Paper 36638096 Paper 36608946 Paper 36288905 Paper 35197258 Paper 34921852 Paper 34166677 Paper 33964299 Paper 33713764 Paper 33712279 Paper 33535024 Paper 33388403 Paper 33301877 Paper 33156902 Paper 32997571 Paper 32380068 Paper 31886690 Paper 31163174 Paper 30529451 Paper 30354704 Paper 30348535 Paper 30106758 Paper 30079758 Paper 29518416 Paper 29449165 Paper 29431692 Paper 29370333 Paper 29288871 Paper 29144432 Paper 29051146 Paper 28939248 Paper 28830083 Paper 28572159 Paper 28296798 Paper 28272497 Paper 28089873 Paper 27654103 Paper 27516235 Paper 27468708 Paper 27452608 Paper 27441734 Paper 26934820 Paper 26885808 Paper 26794640 Paper 26573086 Paper 26551399 Paper 26496766 Paper 26430087 Paper 26409873 Paper 26362696 Paper 26085555 Paper 25979524 Paper 25819170 Paper 25817226 Paper 25794658 Paper 25695886 Paper 25465169 Paper 25409471 Paper 25156271 Paper 25145808 Paper 25133977 Paper 25129677 Paper 25117997 Paper 25090364 Paper 25074637 Paper 25059532 Paper 24971590 Paper 24908147 Paper 24832930 Paper 24821228 Paper 24700865 Paper 24565455 Paper 24485487 Paper 24419071 Paper 24397611 Paper 24392900 Paper 24367482 Paper 24292971 Paper 24275960 Paper 24260137 Paper 24206458 Paper 24192016 Paper 24170933 Paper 24105030 Paper 24060707 Paper 24035186 Paper 24030340 Paper 23988698 Paper 23904290 Paper 23901097 Paper 23841031 Paper 23687224 Paper 23636469 Paper 23595876 Paper 23555914 Paper 23446056

Abstract

The purpose of this study is to determine the virologic benefits and safety of either Nelfinavir (NFZ) or Efavirenz (EFZ) in combination with Indinavir (IDV) and 3TC 150 mg/ZDV 300 mg in the treatment of subjects with advanced HIV disease who have received limited or no prior antiretroviral therapy. The primary endpoints of the study will be time to virologic failure and the safety and tolerance of the three treatment regimens.

View original record on NIH RePORTER →